Multicenter study of the effect of GoLimumab On the Remission Induction rate and bio-free remission maintenance rate in early rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2015
Price : $35 *
At a glance
- Drugs Golimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms GLORIA
- 28 Oct 2015 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 06 Oct 2013 New trial record